x

Angiogenesis

Angiogenesis, the sprouting of new blood vessels from pre-existing vasculature, plays a role in normal physiological processes. It has also been identified as an important target for treatment of a variety of diseases, including cancer. Using our state-of-the-art angiogenesis assay, integrated with our hiPSC-derived vascular endothelial cells, our experts can help you assess the effect of your candidate compounds on the sprouting of new blood vessels.

Benefits

Robust and scalable
High reproducibility and wide assay window, for small and large scale experiments

Physiological relevant cellular microenvironment
through continuous perfusion and exposure to a gradient of angiogenic factors

High quality results
Based on 10+ years of Ncardia experience

Description

Our angiogenesis assay was created during the project “Growing real human small blood vessels in the laboratorium”, in which Ncardia participated together with with Leiden University Medical Center, Leiden Academic Center for Drug Research and Mimetas. The aim of this project was to develop a next generation capillary-on-a-chip model to study mechanisms underlying small blood vessel loss in disease such as ‘heart failure with preserved ejection fraction’.

In the angiogenisis assay, hiPSC-derived endothelial cells are grown in a microfluidic channel. Upon triggering with a gradient of proangiogenic factors, the sprouting cells form an intricate capillary network in an adjacent 3-dimensional matrix. The angiogenesis assay platform (48 devices per plate) is compatible with automated systems for cell plating and imaging, to enable secondary screening.

Click here to watch how our angiogenesis assay was created: Standardized and scalable angiogenesis assay

Case Study

Inhibitory effects of anti-angiogenic compounds

This case study is part of the project Growing real human small blood vessels in the laboratorium.

We developed a perfused 3D angiogenesis assay that includes endothelial cells (ECs) from induced pluripotent stem cells (iPSC) and assessed its performance and suitability for anti-angiogenic drug screening. Angiogenic sprouting was compared with primary ECs and showed that the microvessels from iPSC-EC exhibit similar sprouting behavior, including tip cell formation, directional sprouting and lumen formation.

In this project, we optimized the concentration for sunitinib inhibition, and showed that sunitinib inhibits sprouting from concentrations >10 nM, while angiogenesis is completely inhibited at concentrations >50 nM. Angiogenic sprouts of IPSC-EC's are shown after 48 hours with various concentrations of Sunitinib. (Yellow = F-actin, blue = nucleus). The graphs below show a quantitative analysis, demonstrating the effect of 50 nM Sunitinib.

Click here to read the full article

 

This data was obtained in collaboration with Mimetas and LUMC.

Interested?

Would you like to know more about our angiogenesis assay service?

We're here to listen to your project plans, questions and challenges, and to co-develop a solution that fits your specifications. Please leave your details and message in the form below and we will get back to you as soon as possible.

Related

Manufacturing Service  

Vascular Endothelial cells

News  

Organ-on-Chip Project Award

Article  

Assay Development

Poster  

Assay Development